Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer

Journal of Surgical Oncology

Volumn 99, Issue 5, 2009, Pages 302-306

  Miyoshi, Norikaysu ^a   Yano, Masahiko ^a   Takachi, Ko ^a   Kishi, Kentaro ^a   Noura, Shingo ^a   Eguchi, Hidetoshi ^a   Yamada, Terumasa ^a   Miyashiro, Isao ^a   Ohue, Masayuki ^a   Ohigashi, Hiraoki ^a   Sasaki, Yo ^a   Ishikawa, Osamu ^a   Doki, Yuichiro ^b   Imaoka, Shingi ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Chemoradiotherapy; Esophageal cancer; Toxicity

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ESOPHAGUS CANCER; FEMALE; FEVER; HUMAN; HYDRATION; LEUKOPENIA; MALE; MULTIVARIATE ANALYSIS; NAUSEA; NEPHROTOXICITY; OVERALL SURVIVAL; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; UROGENITAL TRACT DISEASE; VOMITING; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ESOPHAGUS TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PREMEDICATION; SQUAMOUS CELL CARCINOMA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DOXORUBICIN; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUKOPENIA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREMEDICATION; PREOPERATIVE CARE; PROGNOSIS; RADIATION DOSAGE; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 62849116072     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21235     Document Type: Article

References (28)

1. Iizuka: Surgical treatment for A3 esophageal carcinoma. Kyobu Geka 1980;80:822-827 (in Japanese).
2. Ancona E, Ruol A, Castoro C, et al.: First-line chemotherapy improves the resection rate and long-term survival of locally advanced (T4, any N, MO) squamous cell carcinoma of the thoracic esophagus: Final report on 163 consecutive patients with 5-year follow-up. Ann Surg 1997;226:714-723.
3. Takagi I, Karasawa K, Kunishima K, et al.: Surgical treatment of esophageal carcinoma infiltrated to the adjacent organs. Jpn J Gastroenterol Surg 1981; 14:1141-1146 (in Japanese).
4. Nygaard K, Hagen S, Hansen HS, et al.: Preoperative radiotherapy prolongs survival in operable esophageal carcinoma: A randomized, multicenter study of preoperative radiotherapy and chemotherapy. The Second Scandinavian Trial in Esophageal Cancer. World J Surg 1992;16:1104-1110.
5. Le Prise EA, Etienne PL, Meunier BC, et al.: A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994;73:1779-1784.
6. Bosset JF, Gignoux M, Triboulet JP, et al.: Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997;337:161-167.
7. Urba SG, Orringer MB, Turrisi A, et al.: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305-313.
8. Walsh TN, Noonan N, Hollywood D, et al.: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-467.
9. Forastiere AA, Orringer MB, Perez-Tamayo C, et al.: Preoper-ative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: Final report. J Clin Oncol 1993;11: 1118-1123.
10. Apinop C, Putisak P, Preecha N: A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology 1994;41: 391-393.
11. Mandard AM, Dalibard F, Mandard JC, et al.: Pathologic assessment of tumor regression after preoperative chemoradio-therapy of esophageal carcinoma: Clinicopathologic correlations. Cancer 1994;73:2680-2686.
12. Wong G, Chapman JR: Cancers after renal transplantation. Transplant Rev (Orlando) 2008;22:141-149.
13. Brenner MK, Rill DR, Moen RC, et al.: Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993;341:85-86.
14. Burdach S, van Kaick B, Laws HJ, et al.: Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Düsseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol 2000;11: 1451-1462.
15. Tanaka K, Matsunobu T, Sakamoto A, et al.: High-dose chemo-therapy and autologous peripheral blood stem-cell transfusion after conventional chemotherapy for patients with high-risk Ewing's tumors. J Orthop Sei 2002;7:477-482.
16. Al-Faris N, Al Harbi T, Goia C, et al.: Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma? Pediatr Blood Cancer 2007;49:190-195.
17. Ogawa Y, Nishiyama K, Ikesoe J, et al.: Preoperative assessment of tumor invasion of the intrathoracic esophageal carcinoma. In: Siewert JR, Holscher AH, editors. Disease of the esophagus. Berlin, Germany: Springer-Verlag; 1987. pp. 203-206.
18. Sobin LH, Witedkind CH: UICC TNM classification of malignant tumors, 5th edition. New York: Wiley-Liss, Inc.; 1997. pp. 66-69.
19. Kelsen DP, Heelan R, Coonley C, et al.: Clinical and pathological evaluation of response to chemotherapy in patients with esophageal cancer. Am J Clin Oncol 1983;6:539-546.
20. Yano M, Tsujinaka T, Shiozaki H, et al.: Concurrent chemo-therapy (5-fluorouracil and cisplatin) and radiation therapy followed by surgery for T4 squamous cell carcinoma of the esophagus. J Surg Oncol 1999;70:25-32.
21. Marangolo M, Bengala C, Conte PF, et al.: Dose and outcome: The hurdle of neutropenia (review). Oncol Rep 2006:16:233-248.
22. Geh JI, Bond SJ, Bentzen SM, et al.: Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesopha-geal cancer: Evidence of a radiation and chemotherapy dose response. Radiother Oncol 2006;78:236-244.
23. Brahme A: Development of radiation therapy optimization. Acta Oncol 2000;39:579-595.
24. Kempf RA, Mitchell MS: Effects of chemotherapeutic agents on the immune response. II. Cancer Invest 1985;3:23-33.
25. Azuma H, Takahara S, Ichimaru N, et al.: Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY 720, in mouse breast cancer models. Cancer Res 2002;62:1410-1419.
26. Van de Vrie W, Marquet RL, Eggermont AM: Cyclosporin A enhances locoregional metastasis of the CC531 rat colon tumour. J Cancer Res Clin Oncol 1997;123:21-24.
27. Eccles SA, Heckford SE, Alexander P: Effect of cyclosporine A on the growth and spontaneous metastasis of syngeneic animal tumours. Br J Cancer 1980;42:252-259.
28. Hoagland HC: Hematologic complications of cancer chemotherapy. Semin Oncol 1982;9:95-102.